151 related articles for article (PubMed ID: 30573505)
1. Unrelated cord blood transplantation and post-transplant cyclophosphamide.
Bacigalupo A; Sica S; Laurenti L; Sora' F; Giammarco S; Metafuni E; Innocenti I; Autore F; Teofili L; Bianchi M; Chiusolo P
Haematologica; 2019 Feb; 104(2):e77-e78. PubMed ID: 30573505
[No Abstract] [Full Text] [Related]
2. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Lee CJ; Savani BN; Mohty M; Labopin M; Ruggeri A; Schmid C; Baron F; Esteve J; Gorin NC; Giebel S; Ciceri F; Nagler A
Haematologica; 2017 Nov; 102(11):1810-1822. PubMed ID: 28883081
[TBL] [Abstract][Full Text] [Related]
3. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
[TBL] [Abstract][Full Text] [Related]
4. Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
Tanoue S; Konuma T; Takahashi S; Watanabe E; Sato N; Watanabe N; Isobe M; Kato S; Ooi J; Tojo A
Leuk Lymphoma; 2017 Dec; 58(12):2973-2975. PubMed ID: 28509586
[No Abstract] [Full Text] [Related]
5. Unrelated donor umbilical cord blood transplant versus unrelated hematopoietic stem cell transplant in patients with acute leukemia: A meta-analysis and systematic review.
Lou X; Zhao C; Chen H
Blood Rev; 2018 May; 32(3):192-202. PubMed ID: 29174416
[TBL] [Abstract][Full Text] [Related]
6. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
Tomonari A; Takahashi S; Ooi J; Nakaoka T; Takasugi K; Uchiyama M; Tsukada N; Konuma T; Iseki T; Tojo A; Asano S
Eur J Haematol; 2006 Jul; 77(1):46-50. PubMed ID: 16573743
[TBL] [Abstract][Full Text] [Related]
7. Best allogeneic transplantation approach for AML patients in first CR: is delayed unrelated donor bone marrow transplantation better than immediate unrelated cord blood transplantation?
Baron F; Nagler A
Eur J Haematol; 2016 Sep; 97(3):215-6. PubMed ID: 26865252
[No Abstract] [Full Text] [Related]
8. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study.
Baskett J; Culos KA; Satyanarayana G; Patel D; Engelhardt B; Savani B; Jagasia M; Kassim AA; Gatwood KS
Ann Hematol; 2020 May; 99(5):1137-1139. PubMed ID: 32140894
[No Abstract] [Full Text] [Related]
10. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
11. Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis.
Ruggeri A; Volt F; Locatelli F; Michel G; Diaz de Heredia C; Abecasis M; Zecca M; Vora A; Yakouben K; O'Brien TA; Giardino S; Cornish J; Rocha V; Peters C; Bader P; Gluckman E; Dalle JH
Biol Blood Marrow Transplant; 2017 Jan; 23(1):96-102. PubMed ID: 27777140
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT.
Wieczorek M; Labopin M; Castagna L; Brissot E; Socié G; Raiola AM; Angelucci E; Rodríguez AB; Yakoub-Agha I; Aljurf M; Crawley C; Mear JB; Musso M; Fanin R; Avenoso D; Turlure P; Tecchio C; Sanz J; Ciceri F; Nagler A; Mohty M
Am J Hematol; 2023 Feb; 98(2):E41-E44. PubMed ID: 36398703
[No Abstract] [Full Text] [Related]
13. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML.
Kwon M; Bautista G; Balsalobre P; Sánchez-Ortega I; Montesinos P; Bermúdez A; de Laiglesia A; Herrera P; Martin C; Humala K; Zabalza A; Torres M; Bento L; Corral LL; Heras I; Serrano D; Buño I; Anguita J; Regidor C; Duarte R; Cabrera R; Gayoso J; Diez-Martin JL
Bone Marrow Transplant; 2017 Aug; 52(8):1138-1143. PubMed ID: 28346415
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
15. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
[TBL] [Abstract][Full Text] [Related]
17. Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Feliu J; Clay J; Raj K; Barber L; Devlia V; Shaw B; Pagliuca A; Mufti G
Br J Haematol; 2014 Nov; 167(3):426-8. PubMed ID: 24962133
[No Abstract] [Full Text] [Related]
18. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C
Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670
[TBL] [Abstract][Full Text] [Related]
19. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Fedele R; Messina G; Martinello T; Gallo GA; Pontari A; Moscato T; Console G; Dattola A; Princi D; Cuzzola M; Alati C; Ronco F; Molica S; Irrera G; Martino M
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):493-500. PubMed ID: 25034142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
